Literature DB >> 14675713

Impact of steatosis on perioperative outcome following hepatic resection.

David A Kooby1, Yuman Fong, Arief Suriawinata, Mithat Gonen, Peter J Allen, David S Klimstra, Ronald P DeMatteo, Michael D'Angelica, Leslie H Blumgart, William R Jarnagin.   

Abstract

Fatty liver disease may interfere with liver regeneration and is postulated to result in an adverse outcome for patients subjected to partial hepatectomy. This study examines the impact of steatosis on outcome following hepatic resection for neoplasms. All patients with fatty livers (n=325) who underwent hepatectomy between December 1991 and September 2001 were identified from a prospective database. Slides were reviewed and steatosis was quantified as follows: <30% (mild) and > or =30% (marked). Patient data were gathered and compared with results in 160 control patients with normal livers; subjects were matched for age, comorbidity, and extent of liver resection. There were 223 patients with mild and 102 with marked steatosis. Those with steatosis were more likely to be men (59% marked vs. 55% mild vs. 43% control; P=0.01) with a higher body mass index (29.7+/-5.5 marked vs. 28.2+/-5.5 mild vs. 26.0+/-5.4 control; P<0.01), and treated preoperatively with chemotherapy (66% marked vs. 55% mild vs. 38% control; P<0.01). Total (62%, 48%, and 35%; P<0.01) and infective (43%, 24%, and 14%; P<0.01) complications correlated with the degree of steatosis. No difference was observed in complications requiring major medical intervention, hospitalization, or admission to the intensive care unit between groups. On multivariate analysis, steatosis was an independent predictor of complications (P<0.01, risk ratio=3.04, 95% confidence interval=1.7 to 5.54). There was a nonsignificant trend toward higher 60-day mortality in patients with marked steatosis who had lobe or more resections (9.4% marked vs. 5.0% mild vs. 5.0% control; P=0.30). Marked steatosis is an independent predictor of complications following hepatic resection but does not have a significant impact on 60-day mortality. Steatosis alone should not preclude aggressive hepatic resection for neoplasms when indicated; however, patients with marked steatosis undergoing large resections should still be approached with due caution.

Entities:  

Mesh:

Year:  2003        PMID: 14675713     DOI: 10.1016/j.gassur.2003.09.012

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.267


  48 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

Review 2.  Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines.

Authors:  Anna Mae Diehl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-01       Impact factor: 4.052

3.  Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention.

Authors:  Y Fong; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

4.  Fatty liver change as a result of hepatic artery infusion chemotherapy.

Authors:  J Zeiss; H W Merrick; E R Savolaine; L S Woldenberg; K Kim; P J Schlembach
Journal:  Am J Clin Oncol       Date:  1990-04       Impact factor: 2.339

Review 5.  Nonalcoholic fatty liver disease.

Authors:  F Schaffner; H Thaler
Journal:  Prog Liver Dis       Date:  1986

6.  Liver regeneration and hepatic collagen deposition in rats with dimethjylnitrosamine-induced cirrhosis.

Authors:  A Haney; E E Peacock; J W Madden
Journal:  Ann Surg       Date:  1972-06       Impact factor: 12.969

7.  Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.

Authors:  I R Wanless; J S Lentz
Journal:  Hepatology       Date:  1990-11       Impact factor: 17.425

8.  Hepatic resection for metastatic colorectal cancer results in cure for some patients.

Authors:  R L Jamison; J H Donohue; D M Nagorney; C B Rosen; W S Harmsen; D M Ilstrup
Journal:  Arch Surg       Date:  1997-05

9.  Body-mass index and mortality in a prospective cohort of U.S. adults.

Authors:  E E Calle; M J Thun; J M Petrelli; C Rodriguez; C W Heath
Journal:  N Engl J Med       Date:  1999-10-07       Impact factor: 91.245

10.  Liver histology after current intensified therapy for childhood acute lymphoblastic leukemia: microvesicular fatty change and siderosis are the main findings.

Authors:  Päivi Halonen; Jorma Mattila; Tarja Ruuska; Matti K Salo; Anne Mäkipernaa
Journal:  Med Pediatr Oncol       Date:  2003-03
View more
  105 in total

1.  NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis.

Authors:  Tarsila Ribeireiro; James Swain; Michael Sarr; Michael Kendrick; Florencia Que; Schuyler Sanderson; Anuradha Krishnan; Kimberly Viker; Kymberly Watt; Michael Charlton
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

2.  Body mass index and adverse perioperative outcomes following hepatic resection.

Authors:  Amit K Mathur; Amir A Ghaferi; Nicholas H Osborne; Timothy M Pawlik; Darrell A Campbell; Michael J Englesbe; Theodore H Welling
Journal:  J Gastrointest Surg       Date:  2010-06-08       Impact factor: 3.452

3.  Hepatic steatosis prevents heme oxygenase-1 induction by isoflurane in the rat liver.

Authors:  Patrick Stoll; Christian I Schwer; Ulrich Goebel; Hartmut Buerkle; Alexander Hoetzel; Rene Schmidt
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

4.  Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease.

Authors:  Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Pavel Vladimirovich Korita; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

5.  Perfusion CT findings in liver of patients with tumor during chemotherapy.

Authors:  Qing Zhang; Zhen-Guo Yuan; Dao-Qing Wang; Zhi-Hui Yan; Jun Tang; Zuo-Qin Liu
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

Review 6.  The effects of cancer chemotherapy on liver imaging.

Authors:  Philip J A Robinson
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

Review 7.  Drug-induced steatohepatitis.

Authors:  Vaishali Patel; Arun J Sanyal
Journal:  Clin Liver Dis       Date:  2013-09-04       Impact factor: 6.126

8.  Safety and outcomes following resection of colorectal liver metastases in the era of current perioperative chemotherapy.

Authors:  Ilia Gur; Brian S Diggs; Jesse A Wagner; Gina M Vaccaro; Charles D Lopez; Brett C Sheppard; Susan L Orloff; Kevin G Billingsley
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

9.  Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.

Authors:  Matteo Donadon; Jean-Nicolas Vauthey; Evelyne M Loyer; Chusilp Charnsangavej; Eddie K Abdalla
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

10.  Good candidates for a third liver resection of colorectal metastasis.

Authors:  Shintaro Yamazaki; Tadatoshi Takayama; Shunji Okada; Atsuko Iwama; Yutaka Midorikawa; Masamichi Moriguchi; Hisashi Nakayama; Tokio Higaki; Masahiko Sugutani
Journal:  World J Surg       Date:  2013-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.